Phase II Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Feb 2025 According to Kairos Pharma media release, company ounces the addition of Huntsman Cancer Institute in Salt Lake City, Utah to support this Phase 2 clinical trial.
21 Jan 2025 According to Kairos Pharma media release, the company expects to report safety data and interim efficacy data, with an initial readout in first half of 2025.
03 Dec 2024 According to Kairos Pharma media release, the company announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients; The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute (NCI).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com